| Health / Medical Topics |
ALVAC-ESO-1 Vaccine
A cancer vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) encoding the cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC-ESO-1 vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-1-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells. (NCI Thesaurus)
YOU MAY ALSO LIKE
A cancer vaccine made with a form of the canarypox virus that does not cause disease in people. It is being studied…
A cancer vaccine that uses a viral vector system derived from the canarypox virus engineered to target the carcinoembryonic antigen (CEA). It…
A replication-defective recombinant canarypox virus (ALVAC) that contains the entire human carcinoembryonic antigen (CEA) gene. Vaccination with ALVAC-CEA (VCP248) may stimulate…
A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus. ALVAC-CEA (6D)-B7.1 vaccine expresses both…
A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus. ALVAC-B7-CEA expresses carcinoembryonic antigen (CEA),…
A derivative of the Canarypox Virus, ALVAC can infect mammalian cells but it can't replicate. Thus, it produces a self-limiting infection…
